Efficacy of Lazolex® Gel in the Treatment of Herpes Simplex

Iveriapharma LLC30 enrolled

Overview

Study aimed to evaluate the efficacy and tolerance of Lazolex®, an emollient gel, to treat mucocutaneous lesions caused by herpes simplex virus.

A single-center, single-arm, open-label, phase II clinical trial was conducted with 30 patients divided into two groups: 15 patients with herpes simplex virus type 1 (HSV-1) infections and 15 with herpes simplex virus type 2 (HSV-2) infections. All received topical treatment with Lazolex® Gel four times daily for 10 days. The efficacy and tolerance of the treatment were evaluated on day 10 and day 20 after the study started. In addition, recurrence rates were evaluated before treatment with Lazolex® and after a 4-year follow-up period after treatment.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

HSV Infection

Interventions

walnut extractDRUG

Four times a day over a 10-day period

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * diagnosis of acute or chronic herpes simplex mucocutaneous infection, * mild course of disease (defined as body temperature \<37.2°C and without signs of general infirmity), * application of last treatment for herpes simplex infection \>3 months, * available to cooperate during the study, * provision of written informed consent. Exclusion Criteria: * abnormal laboratory results, * hypersensitivity to the product or its components, * pregnancy or breastfeeding, * acute/ chronic renal or liver failure, * history of migraine, * organic brain lesion, * generalized anxiety disorder, * blood supply disturbance in the vertebrobasilar pool, * stage 3 essential hypertension, * concomitant acute or decompensated disease that could affect the study results, * intake of acyclovir, antibiotics, immunosuppressants, antimetabolites, or glucocorticosteroids during 3-month period prior to the study, * concomitant participation in another clinical trial.

Outcomes

Primary Outcomes

Course of the disease

Lazolex® Gel was classified as effective if herpes lesions improved or healed after treatment. The median effective time (ET50), defined as the time (in days) needed to reach complete recovery in 50% of the patients, was used as the main variable for Lazolex® Gel efficacy.

Time frame: 10 days

Change in outbreak frequency

Time frame: 10 days

Change in outbreak frequency

Change in outbreaks along time

Time frame: 4 years

Secondary Outcomes

The degree of patient satisfaction

The level of patient satisfaction with treatment efficacy was categorized as high, medium, or low using a self-questionnaire.

Time frame: 10 days

Number of complaints and symptoms

Tolerance outcomes were evaluated using both objective and subjective criteria. The objective criteria included the comparison of laboratory tests and physical examinations before and after Lazolex® Gel treatment. The subjective criteria included complaints and symptoms reported by patients. In the event of adverse reactions, they were assessed by attending physicians. Individual tolerance was categorized as follows: Very satisfactory: No clinically significant changes in physical examination or laboratory tests, and no adverse reactions. Satisfactory: Insignificant changes in physical examination or laboratory tests, or mild adverse reactions that do not require a change in treatment. Unsatisfactory: Significant changes in physical examination or laboratory tests and/or the occurrence of adverse reactions that require the withdrawal of the product, as well as prescribing treatment to address the adverse reaction

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.